Buchumschlag

Oncogenic IRF3 Signaling Promotes Diffused Large B‐Cell Lymphoma Proliferation by Cyclin D3/CDK4‐Dependent Cell Cycle Control

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Bide Zhao, Linjing Shi, Xiao Yang
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Hematological Oncology
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Knockdown of VDAC1 Promotes Ferroptosis in Diffuse Large B‐Cell Lymphoma
von: Chuanming Lin, et al.
Veröffentlicht: (2025)

RETRACTION: Burkitt Lymphoma Versus Diffuse Large B‐Cell Lymphoma: A Practical Approach
Veröffentlicht: (2026)

MerTK is Ectopically Expressed and Affects the Biological Function in Diffuse Large B‐Cell Lymphoma
von: Yan Li, et al.
Veröffentlicht: (2025)

Molecular Features of Diffuse Large B‐Cell Lymphoma Associated With Primary Treatment Resistance
von: Allison M. Bock, et al.
Veröffentlicht: (2024)

Comprehensive Analysis of Single‐Cell and Bulk Transcriptomics Identified Regulatory T‐Cell Features as Predictors of Prognosis in Diffuse Large B‐Cell Lymphoma
von: Yaoli Cui, et al.
Veröffentlicht: (2025)

Genetic and Transcriptomic Profiles Identify Potential Therapeutic Targets of Concurrent Follicular and Diffuse Large B‐Cell Lymphoma and Transformed Follicular Lymphoma
von: Rui Sun, et al.
Veröffentlicht: (2026)

Polatuzumab Vedotin and Glofitamab for Relapsed/Refractory Diffuse Large B‐Cell Lymphoma in the Compassionate Use Program in Italy
von: Pier Luigi Zinzani, et al.
Veröffentlicht: (2025)

Post‐CAR T‐Cell Therapy Failure Metabolic Parameters Predict Survival and Response in Large B‐Cell Lymphoma
von: Hazim S. Ababneh, et al.
Veröffentlicht: (2024)

Synthetic Lethal Combinations of DNA Repair Inhibitors and Genotoxic Agents to Target High‐Risk Diffuse Large B Cell Lymphoma
von: Sara Ovejero, et al.
Veröffentlicht: (2025)

Upregulated miR‐29a‐3p Prevent Malignant Features of Lymphoma Cells by Targeting MCL1
von: Tengfei Shi, et al.
Veröffentlicht: (2025)

Treatments and Outcomes of Newly Diagnosed CD5‐Positive Diffuse Large B‐Cell Lymphoma: A Multi‐Institutional Observational Study
von: Yuma Nato, et al.
Veröffentlicht: (2025)

Peripheral T‐Cell Lymphoma: What's Next?
von: Sang Eun Yoon, et al.
Veröffentlicht: (2025)

Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B‐Cell Lymphoma
von: Juliette Penichoux, et al.
Veröffentlicht: (2025)

Routine Monitoring of CAR‐T‐Cells Expansion and Persistence in Patients With Aggressive Large B‐Cell Lymphoma by Flow Cytometry: A Single‐Center Experience
von: Alexandra Zduniak, et al.
Veröffentlicht: (2025)

Indolent T‐Cell Lymphoma of the Gastrointestinal Tract Associated With Strongyloides Stercoralis Infection
von: Yue Zhao, et al.
Veröffentlicht: (2025)

Outcomes of Bridging Therapy in Patients With Relapsed/Refractory Large B Cell Lymphoma Receiving Third‐Line CAR T
von: Inna Y. Gong, et al.
Veröffentlicht: (2026)

ARAP1‐AS1 Overexpression Increases Diffuse Large B Cell Lymphoma Progression by Sponging miR‐508–5p to Activate the EMP1‐PI3K/AKT Pathway
von: Yamei Chen, et al.
Veröffentlicht: (2025)

Gemcitabine, Carboplatin, Dexamethasone, and Rituximab Versus High‐Dose Cytarabine‐Based Chemotherapy as Second‐Line Treatments for Relapsed or Refractory Diffuse Large B‐Cell Lymphoma
von: Yoshikazu Ikoma, et al.
Veröffentlicht: (2025)

Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B‐Cell Lymphoma
von: Meirav Kedmi, et al.
Veröffentlicht: (2024)

Clinical Outcomes of CD7 CAR‐T Cell Therapy in Relapsed or Refractory T‐Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Patients
von: Jinyan Xiao, et al.
Veröffentlicht: (2025)

A Novel Prognostic Score for Disease Progression and Mortality in Patients With Newly Diagnosed Primary Large B‐Cell Lymphoma of Immune‐Privileged Sites
von: Ganggang Wang, et al.
Veröffentlicht: (2025)

Differential Expression of CD79B, CD19, and PD‐L1 in de Novo and Transformed CD20‐Negative Large B‐Cell Lymphomas
von: Yuto Kaimi, et al.
Veröffentlicht: (2026)

Advancing Mantle Cell Lymphoma Risk Assessment: Navigating a Moving Target
von: Simone Ferrero, et al.
Veröffentlicht: (2025)

Comparative Effectiveness of R‐miniCOMP Versus R‐miniCHOP in Older Non‐Fit Patients With Diffuse Large B‐Cell Lymphoma: Insights From a “Fondazione Italiana Linfomi” Cohort Study
von: Alberto Bavieri, et al.
Veröffentlicht: (2025)

UMG1 Defines a Targetable Subset of T‐Cell Lymphomas and Enables Precision Immunotherapy With a First‐in‐Class CD3ε Bispecific Engager
von: Daniele Caracciolo, et al.
Veröffentlicht: (2026)

Exploratory Analysis of Practical Predictive Indices for the Efficacy of Mogamulizumab in Patients With Aggressive Adult T‐Cell Leukemia‐Lymphoma
von: Yutaka Shimazu, et al.
Veröffentlicht: (2025)

Long‐Term Follow‐Up of Chidamide With Chemotherapy in Untreated Peripheral T‐Cell Lymphoma: One Single Center Real‐World Study in China
von: Jiajie He, et al.
Veröffentlicht: (2026)

Correction to “Defining and Addressing the Current Unmet Medical Needs for the Frontline Treatment of Advanced Stage Aggressive Large B‐Cell Lymphoma: A Perspective From an Ad Hoc Panel of Italian Experts”
Veröffentlicht: (2025)

Lifetime Treatment Trajectories of Mantle Cell Lymphoma: Simulation Based Analysis of 20 Years of Real‐World Data
von: Minna Harmanen, et al.
Veröffentlicht: (2025)

First Line Therapy in Mantle Cell Lymphoma—The Role of BTKi in the Initial Treatment of Transplant‐Eligible and ‐Ineligible Patients
von: E. Silkenstedt, et al.
Veröffentlicht: (2025)

Long‐Term Outcomes and Management Strategies With DA‐R‐EPOCH in Primary Mediastinal B‐Cell Lymphoma: Insights From a Single‐Center Experience
von: Robin Noel, et al.
Veröffentlicht: (2025)

Re: Long‐Term Outcomes and Management Strategies With DA‐R‐EPOCH in Primary Mediastinal B‐Cell Lymphoma: Insights From a Single‐Center Experience
von: Theodoros P. Vassilakopoulos, et al.
Veröffentlicht: (2025)

Prognostic Value of C‐Reactive Protein/Platelet Ratio as a Biomarker Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Malignant Lymphoma
von: Akihiko Izumi, et al.
Veröffentlicht: (2025)

CAR T‐Cell Therapies for Patients With Relapsed and Refractory Aggressive Lymphomas: Real‐World Experiences From a Single Center on the Use of Radiotherapy
von: J.T. Jutzi, et al.
Veröffentlicht: (2025)

Baseline Tumor Burden Assessed With AI‐Guided PET/CT Total Metabolic Tumor Volume (TMTV) and LDH Levels Predict Efficacy of CAR‐T in Aggressive B‐Cell Lymphoma
von: Eugenio Galli, et al.
Veröffentlicht: (2024)

Prognostic Role of Pretreatment Tumor Burden and Dissemination Features From 2‐[ 18 F]FDG PET/CT in Advanced Mantle Cell Lymphoma
von: Domenico Albano, et al.
Veröffentlicht: (2024)

83 | SINGLE CELL ANALYSIS REVEALS EXTENSIVE IMMUNE EXHAUSTION AND MEMORY‐CELL LIKE ORIGIN IN FOLLICULAR LYMPHOMA (FL) WITH INCREASED IRF4 EXPRESSION
von: E. Contreras Guzman, et al.
Veröffentlicht: (2025)

Ibrutinib Dose Adjustment Does Not Impair Treatment Outcome in Mantle Cell Lymphoma: An Italian Real‐Life Multicenter Experience. Results From the REDOT_MCL Study
von: Francesca Maria Quaglia, et al.
Veröffentlicht: (2026)

Lecture 4. Clonal Plasma Cell Precursors
von: Angela Dispenzieri
Veröffentlicht: (2025)

A Multicenter Real‐World Retrospective Study for Brentuximab Vedotin, Cyclophosphamide, Doxorubicin, and Prednisolone for Previously Untreated Patients With CD30‐Positive Adult T‐Cell Leukemia‐Lymphoma
von: Masahito Tokunaga, et al.
Veröffentlicht: (2025)